{"created":"2021-03-01T06:07:36.229020+00:00","id":3770,"links":{},"metadata":{"_buckets":{"deposit":"d361a361-a115-473f-a8eb-48a6513f7b70"},"_deposit":{"id":"3770","owners":[],"pid":{"revision_id":0,"type":"depid","value":"3770"},"status":"published"},"_oai":{"id":"oai:soar-ir.repo.nii.ac.jp:00003770","sets":["461:462"]},"author_link":["6933","6934","6935","6936","6937","6938","6939","6940","6941","6942"],"item_1628147817048":{"attribute_name":"出版タイプ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_ab4af688f83e57aa","subitem_version_type":"AM"}]},"item_6_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2013-06","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"3","bibliographicPageEnd":"530","bibliographicPageStart":"524","bibliographicVolumeNumber":"18","bibliographic_titles":[{"bibliographic_title":"INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY"}]}]},"item_6_description_20":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"We compared the efficacy and safety of 1- and 3-month depots of the luteinizing hormone-releasing hormone (LH-RH) agonist goserelin acetate in prostate cancer patients. Patients were randomly assigned to the Direct Group that received the goserelin 3-month depot or the Switch Group that began with the 1-month depot for the first 3 months and then switched to the 3-month depot. All patients were co-administered the antiandrogen agent bicalutamide. Serum testosterone and prostate-specific antigen (PSA) levels and adverse events were recorded at weeks 4, 8, 12, and 24. Baseline testosterone levels in the Direct and Switch Groups were 4.98 and 5.07 ng/mL, respectively (P = 0.798). At each week, the levels in both groups were a parts per thousand currency sign0.50 ng/mL (castration level) with no significant differences between them. All of the patients in the Switch Group and 98.1 % in the Direct Group had achieved castration levels at week 12, and 100 % had achieved such levels at week 24. Baseline PSA levels in the Direct and Switch Groups were 52.37 and 46.72 ng/mL, respectively (P = 0.793). Levels in both groups dropped continuously, to about 1.0 ng/mL at week 24, with no significant differences between the groups at any time. Three patients in the Direct Group experienced adverse events that were attributed to the co-administered bicalutamide. There was no difference in the efficacy or safety between the 1- and 3-month depots of goserelin when given as initial prostate cancer treatment in combination with bicalutamide. Patients must be monitored for adverse events associated with bicalutamide.","subitem_description_type":"Abstract"}]},"item_6_description_30":{"attribute_name":"資源タイプ（コンテンツの種類）","attribute_value_mlt":[{"subitem_description":"Article","subitem_description_type":"Other"}]},"item_6_description_5":{"attribute_name":"引用","attribute_value_mlt":[{"subitem_description":"INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY. 18(3):524-530 (2013)","subitem_description_type":"Other"}]},"item_6_link_3":{"attribute_name":"信州大学研究者総覧へのリンク","attribute_value_mlt":[{"subitem_link_text":"Ishizuka, Osamu","subitem_link_url":"http://soar-rd.shinshu-u.ac.jp/profile/ja.gmfaHekh.html"},{"subitem_link_text":"Nishizawa, Osamu","subitem_link_url":"http://soar-rd.shinshu-u.ac.jp/profile/ja.WeyeWmyU.html"}]},"item_6_link_67":{"attribute_name":"WoS","attribute_value_mlt":[{"subitem_link_url":"http://gateway.isiknowledge.com/gateway/Gateway.cgi?&GWVersion=2&SrcAuth=ShinshuUniv&SrcApp=ShinshuUniv&DestLinkType=FullRecord&DestApp=WOS&KeyUT=000320456500025"}]},"item_6_publisher_4":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"SPRINGER JAPAN KK"}]},"item_6_relation_47":{"attribute_name":"PubMed","attribute_value_mlt":[{"subitem_relation_name":[{"subitem_relation_name_text":"22552359"}],"subitem_relation_type_id":{"subitem_relation_type_id_text":"https://pubmed.ncbi.nlm.nih.gov/22552359","subitem_relation_type_select":"PMID"}}]},"item_6_relation_48":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_name":[{"subitem_relation_name_text":"10.1007/s10147-012-0413-9"}],"subitem_relation_type_id":{"subitem_relation_type_id_text":"https://doi.org/10.1007/s10147-012-0413-9","subitem_relation_type_select":"DOI"}}]},"item_6_rights_62":{"attribute_name":"権利","attribute_value_mlt":[{"subitem_rights":"The original publication is available at www.springerlink.com"}]},"item_6_source_id_35":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"1341-9625","subitem_source_identifier_type":"PISSN"}]},"item_6_source_id_40":{"attribute_name":"書誌レコードID","attribute_value_mlt":[{"subitem_source_identifier":"AA11086579","subitem_source_identifier_type":"NCID"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Ishizuka,  Osamu","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Nishizawa,  Osamu","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Nishizawa,  Shuji","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Satoh,  Tomoya","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Wajiki,  Masahisa","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Kiyokawa,  Hideo","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Inoue,  Yoshihiro","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Kobayashi,  Shinya","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Mizusawa,  Hiroya","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Nakagawa,  Tatsuo","creatorNameLang":"en"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2015-09-24"}],"displaytype":"detail","filename":"Comparison_efficacy_safety_1-and 3-month_luteinizing.pdf","filesize":[{"value":"192.3 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"Comparison_efficacy_safety_1-and 3-month_luteinizing.pdf","url":"https://soar-ir.repo.nii.ac.jp/record/3770/files/Comparison_efficacy_safety_1-and 3-month_luteinizing.pdf"},"version_id":"58a1d3a0-b419-4806-a873-52b593fe4c00"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"Prostate cancer","subitem_subject_scheme":"Other"},{"subitem_subject":"Androgen deprivation therapy","subitem_subject_scheme":"Other"},{"subitem_subject":"Luteinizing hormone-releasing hormone agonist","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Comparison of efficacy and safety of 1-and 3-month luteinizing hormone-releasing hormone agonist depots as initial therapies for prostate cancer","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Comparison of efficacy and safety of 1-and 3-month luteinizing hormone-releasing hormone agonist depots as initial therapies for prostate cancer","subitem_title_language":"en"}]},"item_type_id":"6","owner":"1","path":["462"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2014-01-21"},"publish_date":"2014-01-21","publish_status":"0","recid":"3770","relation_version_is_last":true,"title":["Comparison of efficacy and safety of 1-and 3-month luteinizing hormone-releasing hormone agonist depots as initial therapies for prostate cancer"],"weko_creator_id":"1","weko_shared_id":-1},"updated":"2022-12-14T04:38:29.059784+00:00"}